Riverain Technologies
Riverain Technologies is a private medical imaging AI company (founded 2004, Miamisburg, Ohio) that sells the ClearRead suite of chest CT and X-ray AI tools — using proprietary vessel/bone suppression — to hospitals, VA medical centers, academic medical centers, and radiology groups globally via per-scan SaaS and OEM channels.
- Company typePrivate
- Founded2004
- HeadquartersMiamisburg, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Riverain Technologies does
Riverain Technologies is a privately held medical imaging AI company founded in 2004 and headquartered in Miamisburg, Ohio. The company develops the ClearRead suite of cardiothoracic imaging software for chest CT and chest X-ray, built around its proprietary Clear Visual Intelligence (CVI) suppression technology that removes interfering structures — ribs, clavicles, blood vessels, and machine noise — to give radiologists an unobstructed view of lung tissue. The two core products, ClearRead CT and ClearRead Xray, operate as modular suites: ClearRead CT includes Vessel Suppress, Detect (nodule segmentation and volumetric measurement), Compare (prior exam comparison), and CAC scoring modules, while ClearRead Xray includes Bone Suppression, Confirm (Enhanced), and Pneumothorax detection. All ClearRead outputs are pushed back into the customer's existing PACS as additional image series, requiring no separate viewer or login.
The company sells primarily through direct enterprise sales to hospitals, health systems, academic medical centers, VA/DoD facilities, radiology groups, and outpatient imaging centers, supplemented by an extensive channel and OEM footprint spanning Siemens Healthineers (syngo.via), Aidoc, Ferrum Health, ConcertAI/TeraRecon, deepcOS, CARPL.ai marketplace, and a master services agreement with Strategic Radiology (1,500+ radiologists). Revenue is generated via SaaS subscriptions on a per-scan usage basis (~$6.00 per scan per the published CAC ROI calculator), with pricing varying by volume and configuration. The VA Lung Precision Oncology Program (LPOP) deployment across 104 VA sites is a flagship federal contract; the company reports 400+ customer locations globally, 4M+ exams processed annually, and 100% customer retention entering 2024. Customer growth has been hyper-growth-tier: 286% YoY in 2023 and 147% YoY in 2024, with 50 new customers added in 2024 and expansion into eight new countries.
Regulatory footprint includes FDA 510(k) clearances (concurrent-read CT vessel suppression), EU MDR certification (February 2022), TGA approval (Australia), Health Canada approval (March 2025 for CAC), and ISO 27001. The company is managed by CEO Steve Worrell, with a leadership team including CCO Mark Koeniguer and CPO Ofer Pinhasi. Clinical evidence includes multiple peer-reviewed studies showing 29% reduction in missed pulmonary nodules, 26–36% faster reading times, 21% greater nodule detection on vessel-suppressed CT, and improved inter-reader agreement. A new Medicare reimbursement pathway (code G0680) for AI-powered CAC scoring on routine chest CTs takes effect April 1, 2026, layering a reimbursement lever on top of the existing SaaS revenue model and significantly expanding the economic case for adoption.
Riverain Technologies firmographics
Firmographics- Name
- Riverain Technologies
- Legal name
- Riverain Technologies
- Website
- https://riveraintech.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Riverain Technologies is a private medical imaging AI company (founded 2004, Miamisburg, Ohio) that sells the ClearRead suite of chest CT and X-ray AI tools — using proprietary vessel/bone suppression — to hospitals, VA medical centers, academic medical centers, and radiology groups globally via per-scan SaaS and OEM channels.
- Ownership category
- akta.pro rank
Riverain Technologies industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industries
- Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories (HLACALAC), Radiology Reporting, Dictation & Structured Reporting (HLACALAF), Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD)
Keywords
Where Riverain Technologies is headquartered
LocationHeadquarters
- HQ city
- Miamisburg
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Riverain Technologies business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Software as a Service (SaaS) Subscription: SaaS pricing model for ClearRead solutions, with per-scan costs. CAC Reimbursement ROI tool references a SaaS cost of $6.00 per scan. Pricing varies by customer volume, study type, and configuration. Revenue recognized through software licensing and subscription contracts with healthcare providers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | CAC Reimbursement Model - Per-scan SaaS + Medicare billing |
Go-to-market motion3 records
Distribution channels8 records
Marketing channels9 records
Riverain Technologies product offering
Product offeringCore offering
Riverain Technologies develops and sells ClearRead, an FDA-cleared AI-powered chest imaging software suite (ClearRead CT for chest CT and ClearRead Xray for chest X-ray) used by radiologists to detect pulmonary nodules, coronary artery calcification, and pneumothorax. The products are built on proprietary Clear Visual Intelligence (CVI) suppression technology that removes bones, vessels, and machine noise from chest images to improve reading accuracy and reduce reading time, and integrate natively into existing PACS workflows.
Product overview
Riverain Technologies offers a unified ClearRead suite of AI-powered chest imaging interpretation solutions built around its proprietary Clear Visual Intelligence (CVI) suppression technology. The portfolio centers on two core products: ClearRead CT (a cardiothoracic AI suite for chest CT scans) and ClearRead Xray (for chest X-rays). These are available as standalone tools or within a modular architecture: ClearRead CT includes Vessel Suppress, Detect, Compare, and CAC Scoring modules; ClearRead Xray includes Bone Suppression, Confirm (Enhanced), and Pneumothorax detection modules. All products integrate directly into PACS systems as additional series within existing workflows, with no separate viewer or login required. The company operates from Miamisburg, Ohio, and serves over 400 customer locations globally with products deployed across hospitals, VA medical centers, and radiology groups.
Differentiator
Problem solved
Functional benefit
Brands
- ClearRead CT: AI-powered cardiothoracic imaging suite for pulmonary nodule detection and coronary artery calcification (CAC) scoring on chest CT scans.
- ClearRead Xray
- Clear Visual Intelligence (CVI)
- Certainty of Search (CoS)
Products and services
- ClearRead CT FDA-cleared AI-powered cardiothoracic imaging suite for chest CT scans used by radiologists to detect, segment, and measure pulmonary nodules and quantify coronary artery calcification (CAC) with Agatston scoring. Built on proprietary vessel suppression technology that removes vascular structures from chest CT images, providing an unimpaired view that improves nodule detection accuracy, supports prior exam comparison, and reduces reading time. Integrates natively into existing PACS systems as an additional image series. Targeted at hospitals, health systems, VA/DoD facilities, academic medical centers, and outpatient imaging centers.
- ClearRead Xray FDA-cleared AI-powered chest X-ray suite that uses patented bone suppression technology to remove ribs and clavicles from frontal chest radiographs, plus computer-assisted detection for pulmonary nodules and pneumothorax. Provides an unimpaired view of the chest to improve detection accuracy and reading workflow, and is device and protocol agnostic, working across all manufacturers' X-ray equipment without additional radiation dose. Integrates natively into existing PACS systems. Targeted at hospitals, health systems, VA/DoD facilities, academic medical centers, and outpatient imaging centers.
Quantifiable outcome
- 29% reduction in missed pulmonary nodules
- +9 more outcomes
Companies that use Riverain Technologies
Customer profileNamed customers27 records
Segments6 records
Ideal customer profiles6 records
Riverain Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration11 records
AI capability3 records
Feature6 records
Riverain Technologies partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered strategic, minor and core.
- VIDA DiagnosticsstrategicVIDA Diagnostics integrates Riverain's AI imaging analysis suite into its clinical trial platform, announced at RSNA conference. Collaboration aims to enhance biomarker data quality and operational efficiency in global clinical trials for COPD, cardiovascular disease, and lung cancer — collectively causing 40% of global deaths. VIDA serves the life sciences and clinical research market.
- deepc (deepcOS)strategicdeepcOS integrates Riverain Technologies' ClearRead solutions into its enterprise health AI operating system. The partnership enriches deepc's enterprise health AI portfolio with Riverain's clinically proven chest imaging AI, extending access to healthcare providers through the deepcOS platform.
- BialogicsminorBialogics and Riverain partnership sets a new benchmark for AI adoption in healthcare imaging. Bialogics provides AI adoption benchmarking and implementation support services that help healthcare organizations integrate Riverain's ClearRead solutions effectively into their imaging workflows.
- Azra AIstrategicAzra AI and Riverain Technologies collaborate to integrate advanced AI for end-to-end lung cancer detection and care coordination. Combines Riverain's ClearRead nodule detection with Azra AI's care coordination and follow-up management to create a comprehensive lung cancer detection and patient management workflow.
- CARPL.aistrategicCARPL.ai adds ClearRead CT and ClearRead Xray to its vendor-neutral AI marketplace, which now offers 160+ AI applications. Partnership expands global access to AI for lung cancer detection by making Riverain's FDA-cleared solutions available alongside other AI tools within a single platform. Enables radiologists to evaluate and implement the best AI solutions for their practice.
- RevealDxstrategicRevealDx and Riverain integrate their products with distribution by Riverain in Canada. RevealDx's RevealAI-Lung software uses a Malignancy Similarity Index (mSI) for patient follow-up recommendations, while Riverain's ClearRead CT provides vessel suppression, nodule detection, and volumetric data. Partnership builds on ClearRead benefits by adding malignancy characterization to improve follow-up recommendations. Riverain distributes RevealDx's technology in Canada.
- Strategic RadiologystrategicMaster Services Agreement with Strategic Radiology, a national coalition of 35 privately owned independent radiology practices representing 1,500+ radiologists. Agreement provides Strategic Radiology member practices access to ClearRead solutions, bringing state-of-the-art AI tools to independent radiology practices to improve quality and efficiency of radiology services.
- Siemens HealthineerscoreExtension of long-standing partnership. ClearRead Xray Bone Suppression is available on Siemens Healthineers syngo.via OpenApps platform and Digital Marketplace, serving customers in Europe and the US. Enables Siemens Healthineers customers to browse, test, download, and request quotations for ClearRead directly through their existing infrastructure. Extension of enterprise solution supporting standard-of-care deployment.
- Ferrum HealthcoreClearRead CT and ClearRead Xray available on Ferrum Health Private AI Hub, the nation's most widely deployed private AI platform for imaging. Partnership enables healthcare providers to access ClearRead with real-time access to the latest medical imaging technology while reducing implementation costs. Brings together two industry leaders with shared goal of accelerating AI adoption.
- ConcertAI TeraReconcoreClearRead CT and ClearRead Xray integrated into ConcertAI's TeraRecon Eureka Clinical AI platform, providing one point of access to clinically proven AI solutions delivered in a streamlined manner into existing physician workflows. Eureka platform serves as a central hub for AI imaging solutions accessible to healthcare providers.
- AidoccoreRiverain and Aidoc partnership integrates Riverain's commercially available FDA-cleared lung nodule detection and measurement algorithms with Aidoc's platform, which serves ~600 medical centers globally. Aidoc provides its PE, incidental PE, and rib fracture modules in exchange. The combined offering delivers a unified cross-specialty AI experience with a seamless workflow, enabling radiologists to read faster while improving patient outcomes. Both companies co-market the integrated chest AI package.
Scale indicators9 records
Recent moves7 records
Expansion highlights7 records
Riverain Technologies competitors and assessment
Company assessmentDirect peers
- Aidoc: Aidoc is a radiology AI platform serving ~600 medical centers with cross-specialty AI modules including PE and rib fracture. Riverain and Aidoc have a formal integration partnership but also compete in adjacent chest AI workflows, making Aidoc the closest direct peer in platform-based radiology AI distribution.
- Annalise.ai: Annalise.ai is a chest X-ray AI vendor offering comprehensive CXR triage and detection across 124+ findings. Directly comparable to ClearRead Xray in clinical use case (chest X-ray AI), target customer (radiology departments), and enterprise SaaS model.
- Qure.ai: Qure.ai is a global radiology AI company with FDA-cleared chest X-ray and head CT products (qXR, qER) targeting pulmonary nodule, TB, and pneumothorax detection. Direct overlap with ClearRead Xray in chest X-ray AI and pulmonary nodule detection, serving similar hospital and emerging-market segments.
- Lunit: Lunit is a Korean publicly-listed medical AI company with Lunit INSIGHT CXR for chest X-ray anomaly detection (including nodule and pneumothorax) and Lunit INSIGHT MMG for mammography. Direct chest X-ray AI competitor with global enterprise hospital footprint comparable to ClearRead Xray's go-to-market.
- VIDA Diagnostics: VIDA Diagnostics is a lung imaging AI company focused on quantitative CT analysis for clinical trials and COPD/emphysema phenotyping. Direct peer in lung CT imaging AI, formally partnered with Riverain for clinical trial biomarker applications, serving overlapping pharmaceutical and academic medical center customers.
- RevealDx: RevealDx offers RevealAI-Lung, a malignancy probability scoring tool for lung nodules on CT that integrates with ClearRead CT. Direct peer in lung cancer screening AI, with formal partnership for combined nodule detection plus malignancy characterization workflow in Canada.
Broad incumbents
- Siemens Healthineers: Siemens Healthineers is the OEM partner distributing ClearRead through its syngo.via OpenApps and Digital Marketplace, but it is also a broad incumbent that develops its own AI Radiology Assistants and bundles imaging AI across CT, MR, and X-ray. Comparable as the dominant imaging modality vendor with overlapping chest AI offerings.
- GE HealthCare: GE HealthCare is a global imaging equipment and AI vendor offering Edison AI platform with chest imaging applications including nodule detection and lung screening. Broad incumbent comparable as integrated imaging modality + AI provider competing for similar enterprise hospital and lung screening program contracts.
- Philips (Philips HealthSuite / AI Manager): Philips operates an AI Manager platform integrating third-party and proprietary radiology AI applications across CT, MR, and X-ray. Broad incumbent comparable as large modality vendor with chest CT/X-ray AI capabilities distributed through enterprise hospital contracts overlapping Riverain's customer base.
Emerging players
- Deepc: Deepc operates the deepcOS enterprise health AI operating system and integrates third-party radiology AI including ClearRead. Comparable as a radiology AI orchestration platform and marketplace partner, with emerging overlap in chest imaging deployment to European hospital systems.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Riverain Technologies social profiles
Digital presenceRiverain Technologies compliance and trust
Trust signalCompliance7 records
Riverain Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Riverain Technologies leadership team
Management profileNumber of profiles
Profiles16 records
Riverain Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Riverain Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Riverain Technologies
What does Riverain Technologies do?
Riverain Technologies develops and sells ClearRead, an FDA-cleared AI-powered chest imaging software suite (ClearRead CT for chest CT and ClearRead Xray for chest X-ray) used by radiologists to detect pulmonary nodules, coronary artery calcification, and pneumothorax. The products are built on proprietary Clear Visual Intelligence (CVI) suppression technology that removes bones, vessels, and machine noise from chest images to improve reading accuracy and reduce reading time, and integrate natively into existing PACS workflows.
Is Riverain Technologies a public or private company?
Riverain Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Riverain Technologies founded?
Riverain Technologies was founded in 2004. It employs 11 to 50 people.
Where is Riverain Technologies based?
Riverain Technologies is headquartered in Miamisburg, United States, in the North America region.
How does Riverain Technologies make money?
One revenue line is on record: software as a Service (SaaS) Subscription.
Who are Riverain Technologies's main competitors?
Direct peers on record are Aidoc, Annalise.ai, Qure.ai, Lunit, VIDA Diagnostics and RevealDx. Broad incumbents are Siemens Healthineers, GE HealthCare and Philips (Philips HealthSuite / AI Manager). Deepc is listed as an emerging player.
Does Riverain Technologies have an API?
No public API is recorded for Riverain Technologies.
What industry is Riverain Technologies in?
Riverain Technologies's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories. Its NAICS code is 325413 and its SIC code is 2835.